Lucid Diagnostics Inc. and majority-owned subsidiary of PAVmed Inc. announced that three manuscripts providing interim results from the Prospective REView of Esophageal Precancer DetectioN in AT-Risk Patients (PREVENT) Registry, the CLUE) study, and full data from the San Antonio Firefighter study, have been published--the first peer-reviewed publications demonstrating real- world clinical utility of Lucid's EsoGuard®? Esophageal DNA test to detect esophageal precancer. The publications are: PREVT R Registries - Englehardt R, Samarasena JB, Bildzukewicz NA, Hamblin R, e VT, deGuzman BJ, Aklog L. (2(2023).

J Gastro & Digestive Systems, 7(2), 43-53. Interim analysis of409 of 517 enrolled patients with complete clinical utility data in the PREVENT and PREVENT-FF registries of patients undergoing EsoGuard testing by Lucid personnel. CLUE Study - Lister D, Fine A, Maheshwari S, Bradley PS, Lee VT, deGuzman BJ., Verma S, Aklog L. Clinical Utility of EsoGuard(R) on Samples collected with EsoCheck(R) as a Triage to Endoscopy for Identification of Bararrett's Esophagus -- Interim Data from the CLUE Study.

Archives of Clinical and Biomedical Research, 7 (2023): 626-634. Interim analysis of 220 of 275 enrolled patients with complete clinical utility Data in the prospective, multicenter CLUE study of at-risk patients referred for EsoGuard testing. San Antonio Firefighter Study - Hamblin R, Lee VT, DeGuzman BJ, Verma S, Ak Log L (2023).

These results demonstrate that, in real-world use, EsoGuard allows physicians to appropriately triage at-risk patients, consistent with established professional society guidelines, and ensure cost-effective utilization of endoscopy in esophageal precancer detection. The CLUE study has completed enrollment and data from the full cohort of over 500 patients, including data on patient compliance with referral for endoscopy, will be released and submitted for publication when patient follow-up and data analysis is complete. The PREVENT registries are open-ended and have enrolled over 600 patients to date, penetrating even further into the patient journey, beyond the initial medical decision-making.